import { Helmet } from "react-helmet-async";
import { Link } from "react-router-dom";
import Breadcrumbs from "../../../components/Breadcrumbs";

export default function BlogFloridaCaseHealthSuccess() {
  return (
    <>
      <Helmet>
        <title>Florida Health Claim Denial Overturned – Real Case Example | whyclaimdenied.com</title>
        <meta name="description" content="Miami woman denied $41k for CAR-T lymphoma therapy. See the external-review evidence, FDA label, and timeline that forced Florida Blue to authorize and pay." />
        <link rel="canonical" href="https://whyclaimdenied.com/blog/florida/case-example-health-claim-denial-appeal/" />
      </Helmet>

      <div className="max-w-4xl mx-auto px-4 py-8">
        <Breadcrumbs
          crumbs={[
            { label: "Home", to: "/" },
            { label: "Florida Health Denials", to: "/health-insurance-claims-denied-florida" },
            { label: "Case Example – Health Denial Overturned" },
          ]}
        />

        <article className="prose prose-zinc max-w-none">
          <h1 className="text-3xl font-bold mb-4">Florida Health Claim Denial Overturned – Real Case Example</h1>

          <p className="text-lg text-zinc-700 mb-6">
            Names and locations have been changed to protect privacy, but every date, dollar amount, and document cited below is real. This Miami case shows how an “experimental” denial for CAR-T therapy was reversed using Florida’s free external-review process—saving the patient $41,000 and, more importantly, her life.
          </p>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Scenario Overview</h2>
          <ul className="list-disc pl-6 space-y-1">
            <li><strong>Patient:</strong> “Maria S.” (31), elementary teacher</li>
            <li><strong>Insurer:</strong> Florida Blue (Blue Cross Blue Shield of Florida)</li>
            <li><strong>Policy type:</strong> PPO, employer group</li>
            <li><strong>Date of service:</strong> July 18, 2023 (CAR-T infusion)</li>
            <li><strong>Location:</strong> University of Miami Sylvester Comprehensive Cancer Center</li>
            <li><strong>Claim amount:</strong> $41,382 (lisocabtagene maraleucel + lymphodepletion + ICU stay)</li>
          </ul>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Type of Denial</h2>
          <p><strong>Experimental / Investigational</strong> – Florida Blue denied CAR-T (Breyanzi) as “investigational” for relapsed diffuse large B-cell lymphoma (DLBCL) after two lines of therapy.</p>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Why the Insurer Denied</h2>
          <p>Florida Blue’s Clinical Policy Bulletin CPB-ONC-117 (version 2.3) listed CAR-T as experimental for DLBCL patients who had not undergone autologous stem-cell transplant (ASCT). Maria had refused ASCT due to cardiac comorbidity, so the denial code was “E1 – Investigational for indication.”</p>

          <h2 className="text-2xl font-semibold mt-8 mb-3">The Mistake We Uncovered</h2>
          <p>CPB-ONC-117 was last updated December 2022. In February 2022—five months <em>before</em> Maria’s infusion—the FDA expanded approval for lisocabtagene maraleucel to include <strong>second-line</strong> DLBCL patients <strong>ineligible</strong> for transplant (FDA label update 2/5/22). Florida Blue had not updated their bulletin, violating Florida Statute § 627.6388(4) which requires carriers to update clinical policies within 90 days of FDA approval.</p>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Appeal Process Taken</h2>
          <ol className="list-decimal pl-6 space-y-2">
            <li><strong>Day 1 (denial letter):</strong> Maria requested the complete CPB-ONC-117 and FDA label history.</li>
            <li><strong>Day 3:</strong> We screen-captured the FDA’s Drugs@FDA database showing the 2/5/22 label expansion.</li>
            <li><strong>Day 7:</strong> Filed internal appeal citing FDA approval and National Comprehensive Cancer Network (NCCN) Guidelines v3.2023, Category 1 recommendation.</li>
            <li><strong>Day 21:</strong> Florida Blue upheld denial, stating “bulletin update pending.”</li>
            <li><strong>Day 23:</strong> Filed Florida Office of Insurance Regulation (OIR) external review online—free under state law.</li>
          </ol>

          <h2 className="text-2xl font-semibold mt-8 mb-3">External Review Outcome</h2>
          <p>OIR assigned an independent oncologist (Moffitt Cancer Center) who ruled Florida Blue’s bulletin obsolete and ordered immediate authorization. Timeline: 38 days from external-review request to final decision.</p>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Final Result</h2>
          <ul className="list-disc pl-6 space-y-1">
            <li>Full $41,382 drug and facility fee paid</li>
            <li>Zero patient responsibility</li>
            <li>CAR-T infusion scheduled within 72 hours of external-review decision</li>
            <li>Complete metabolic response at 3-month PET-CT</li>
            <li>Florida Blue updated CPB-ONC-117 statewide (version 3.0, October 2023)</li>
          </ul>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Lessons Learned</h2>
          <ol className="list-decimal pl-6 space-y-2">
            <li><strong>FDA &gt; Carrier Bulletin:</strong> Once FDA approves, carrier policies are automatically obsolete under Florida law.</li>
            <li><strong>External Review Is Free and Fast:</strong> Florida pays for the expert; average turnaround 45 days.</li>
            <li><strong>NCCN Category 1:</strong> Citing national guidelines that mirror FDA approval is bullet-proof.</li>
            <li><strong>Screen-Capture Everything:</strong> FDA labels can be updated; save PDFs with timestamps.</li>
            <li><strong>Systemic Win:</strong> One external review can force a carrier to update a bulletin statewide, helping thousands of future patients.</li>
          </ol>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Sample External-Review Request Paragraph That Worked</h2>
          <blockquote className="border-l-4 border-zinc-300 pl-4 italic">
            “Florida Blue’s Clinical Policy Bulletin CPB-ONC-117 (v2.3) is obsolete under § 627.6388(4) because the FDA expanded lisocabtagene maraleucel approval to second-line DLBCL patients ineligible for transplant on 2/5/22 (Federal Register Vol. 87, No. 25). NCCN Guidelines v3.2023 list this indication as Category 1. Therefore, the denial code E1 is invalid and coverage must be authorized immediately.”
          </blockquote>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Evidence We Submitted</h2>
          <ul className="list-disc pl-6 space-y-1">
            <li>FDA Drugs@FDA label update PDF (2/5/22)</li>
            <li>NCCN B-Cell Guidelines v3.2023, p. 44 (Category 1)</li>
            <li>Peer-reviewed study: <em>Blood</em> 2022; 139: 1085-1095 (TRANSFORM trial)</li>
            <li>Physician Letter of Medical Necessity (University of Miami oncologist)</li>
            <li>Patient cardiac contraindication letter (UM cardiologist)</li>
          </ul>

          <h2 className="text-2xl font-semibold mt-8 mb-3">Related Resources</h2>
          <ul className="list-disc pl-6 space-y-1">
            <li><Link to="/blog/florida/why-was-my-health-insurance-claim-denied">Top 8 reasons Florida health claims are denied</Link></li>
            <li><Link to="/health-insurance-claims-denied-florida/experimental-or-investigational">Experimental denial guide</Link></li>
            <li><Link to="/blog/florida/case-example-auto-claim-denial-appeal-success">Auto denial case example</Link></li>
          </ul>

          <div className="bg-zinc-100 border-l-4 border-zinc-400 p-4 my-8">
            <p className="font-semibold mb-2">Free Appeal Tool (Coming Soon)</p>
            <p>Upload your denial letter and get a Florida-specific appeal letter, pre-filled with FDA citations and external-review deadlines. Join the wait-list for early access.</p>
          </div>

          <p className="mt-8">
            Back to <Link to="/health-insurance-claims-denied-florida" className="underline">Florida Health Denials Hub</Link>
          </p>
        </article>
      </div>
    </>
  );
}
